Angiogenic Factor AGGF1 Promotes Therapeutic Angiogenesis in a Mouse Limb Ischemia Model

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lu, Qiulun ^a   Yao, Yihong ^a   Yao, Yufeng ^a   Liu, Shizhi ^a   Huang, Yuan ^a   Lu, Shan ^a   Bai, Ying ^a   Zhou, Bisheng ^a   Xu, Yan ^a   Li, Lei ^a   Wang, Nan ^a   Wang, Li ^a   Zhang, Jie ^a   Cheng, Xiang ^b   Qin, Gangjian ^c   Ma, Wei ^d   Xu, Chengqi ^a   Tu, Xin ^a   Wang, Qing ^a,e  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

^d First Hospital of Wuhan City   (China)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CD31 ANTIGEN; MESSENGER RNA; PLASMID DNA; PROTEIN AGGF1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DOPPLER ECHOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE TRANSFER; HINDLIMB; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE NECROSIS; UPREGULATION;

ANGIOGENIC PROTEINS; ANIMALS; HINDLIMB; HUMANS; ISCHEMIA; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE;

EID: 84867869521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046998     Document Type: Article

References (41)

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, et al. (2006) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol 47: 1239-1312.
2. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, et al. (1994) Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94: 3026-3049.
3. Rooke T, Hirsch AT, Misra S, Sidawy A, Beckman J, et al. (2011) 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 58: 2020-2045.
4. Hiatt WR, (2001) Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344(21): 1608-1621.
5. Selvin E, Erlinger TP, (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110: 738-743.
6. Lange S, Diehm C, Darius H, Haberl R, Allenberg JR, et al. (2003) High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes. Diabetes Care 26: 3357-3358.
7. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, et al. (1996) Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25: 1172-1181.
8. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, et al. (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381-386.
9. Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, et al. (2003) Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vasc Med 8: 233-236.
10. Welten GM, Schouten O, Chonchol M, Hoeks SE, Bax JJ, et al. (2009) Prognosis of patients with peripheral arterial disease. J Cardiovasc Surg 50: 109-121.
11. Vogt MT, Wolfson SK, Kuller LH, (1992) Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol 45: 529-542.
12. Brevetti G, Giugliano G, Brevetti L, Hiatt WR, (2010) Inflammation in peripheral artery disease. Circulation 122: 1862-1875.
13. Olin JW, Sealove BA, (2010) Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 85(7): 678-692.
14. Costantini V, Lenti M, (2002) Treatment of acute occlusion of peripheral arteries. Thromb Res 106(6): V285-294.
15. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, et al. (2008) Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 51: 1588-1596.
16. Gupta R, Tongers J, Losordo DW, (2009) Human studies of angiogenic gene therapy. Circ Res 105: 724-736.
17. Matyas L, Schulte KL, Dormandy JA, Norgren L, Sowade O, et al. (2005) Arteriogenic gene therapy in patients with unreconstructable criticallimb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther 16(10): 1202-1211.
18. Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S, (2012) Gene therapy in the treatment of peripheral arterial disease. Br J Surg 99: 6-15.
19. Tongers J, Roncalli JG, Losordo DW, (2008) Therapeutic angiogenesis for critical limb ischemia: Microvascular therapies coming of age. Circulation118: 9-16.
20. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, et al. (2000) Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132: 880-884.
21. Tian XL, Kadaba R, You SA, Liu M, Timur AA, et al. (2004) Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 427(6975): 640-645.
22. Hu Y, Li L, Seidelmann SB, Timur AA, Shen PH, et al. (2008) Identification of association of common AGGF1 variants with susceptibility for Klippel-Trenaunay syndrome using the structure association program. Ann Hum Genet 72(Pt5): 636-643.
23. Fan C, Ouyang P, Timur AA, He P, You SA, et al. (2009) Novel roles of GATA1 in regulation of angiogenic factor AGGF1 and endothelial cell function. J Biol Chem 284: 23331-23343.
24. Hiraoka K, Koike H, Yamamoto S, Tomita N, Yokoyama C, et al. (2003) Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA. Circulation 108: 2689-2696.
25. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG, (1993) Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 4(6): 733-740.
26. Powell RJ, Dormandy J, Simons M, Morishita R, Annex BH, (2004) Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial. Vasc Med 9: 193-198.
27. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, et al. (2008) Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 16: 972-978.
28. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, et al. (1996) Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281-3290.
29. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, et al. (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 8(3): 181-189.
30. Zhang T, He P, Wang Q, (2008) Aggf1 is essential for embryonic and pathological angiogenesis. Circulation 118: S461-S462.
31. Timur AA, Driscoll DJ, Wang Q, (2005) Biomedicine and diseases: the Klippel-Trenaunay syndrome, vascular anomalies and vascular morphogenesis. Cell Mol Life Sci 62(13): 1434-1447.
32. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, et al. (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15(5): 837-846.
33. Helisch A, Wagner S, Khan N, Drinane M, Wolfram S, et al. (2006) Impact of mouse strain differences in innate hindlimb collateral vasculature. Arterioscler Thromb Vasc Biol 26: 520-526.
34. Limbourg A, Korff T, Napp LC, Schaper W, Drexler H, et al. (2009) Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 4: 1737-1746.
35. Ha XQ, Liu B, Qian Z, Lü TD, Hui L, et al. (2008) Hepatocyte growth factor gene transfer effects on the femoral and intramuscular nerve in a canine model of lower limb ischemia. Neural Regen Res 3(6): 625-628.
36. Schgoer W, Theurl M, Jeschke J, Beer AG, Albrecht K, et al. (2009) Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism. Circ Res 105: 994-1002.
37. Fitzgerald SM, Bashari H, Cox JA, Parkington HC, Evans RG, (2007) Contributions of endothelium-derived relaxing factors to control of hindlimb blood flow in the mouse in vivo. Am J Physiol Heart Circ Physiol 293: H1072-H1082.
38. Qi X, Okamoto Y, Murakawa T, Wang F, Oyama O, et al. (2010) Sustained delivery of sphingosine-1-phosphate using poly(lactic-co-glycolic acid)-based microparticles stimulates Akt/ERK-eNOS mediated angiogenesis and vascular maturation restoring blood flow in ischemic limbs of mice. Eur J Pharmacol 634(1-3): 121-131.
39. Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, et al. (2007) Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 101: 1310-1318.
40. Wang F, Xu CQ, He Q, Cai JP, Li XC, et al. (2011) Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet 43(4): 345-349.
41. Wu L, Yong SL, Fan C, Ni Y, Yoo S, et al. (2008) Identification of a new co-factor, MOG1, required for the full function of cardiac sodium channel Nav1.5. J Biol Chem 283: 6968-6978.